Detection of driver mutations acquired very early in life and life-long clonal expansion may predict clinical outcomes and interventions for patients with myeloproliferative neoplasms.
Although mycophenolate is often used as second-line treatment for immune thrombocytopenia, its efficacy as first-line treatment in combination with corticosteroids is unknown.
Among patients with HIV-associated Burkitt lymphoma, intensive regimens containing rituximab may be linked to favorable survival outcomes.
Investigators assessed mortality rates and other outcomes in patients with hematologic malignancies and COVID-19 infection.
Initial treatment of mantle cell lymphoma with lenalidomide and rituximab may result in significant complete response rates and durable lengths of remission.
Researchers characterized hospitalization and case fatality rates secondary to COVID-19 among individuals with SCD and compared with the general Black population.
Researchers have identified the binding site for LRF as a therapeutic target for β-hemoglobinopathies.
Venetoclax in combination with fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin may benefit patients with treatment-naive or relapsed/refractory acute myeloid leukemia.
Researchers evaluated the cumulative incidence of intracranial and extracranial arteriopathy and associated risk factors in children with sickle cell disease.
Investigators retrospectively assessed whether previous TKI therapy may affect response and survival outcomes in patients with relapsed or refractory acute myeloid leukemia.
